Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 78

1.

RNA Therapeutics in Oncology: Advances, Challenges, and Future Directions.

MacLeod AR, Crooke ST.

J Clin Pharmacol. 2017 Oct;57 Suppl 10:S43-S59. doi: 10.1002/jcph.957. Review.

PMID:
28921648
2.

Targeting DMPK with Antisense Oligonucleotide Improves Muscle Strength in Myotonic Dystrophy Type 1 Mice.

Jauvin D, Chrétien J, Pandey SK, Martineau L, Revillod L, Bassez G, Lachon A, MacLeod AR, Gourdon G, Wheeler TM, Thornton CA, Bennett CF, Puymirat J.

Mol Ther Nucleic Acids. 2017 Jun 16;7:465-474. doi: 10.1016/j.omtn.2017.05.007. Epub 2017 May 17.

3.

Targeting KRAS-dependent tumors with AZD4785, a high-affinity therapeutic antisense oligonucleotide inhibitor of KRAS.

Ross SJ, Revenko AS, Hanson LL, Ellston R, Staniszewska A, Whalley N, Pandey SK, Revill M, Rooney C, Buckett LK, Klein SK, Hudson K, Monia BP, Zinda M, Blakey DC, Lyne PD, Macleod AR.

Sci Transl Med. 2017 Jun 14;9(394). pii: eaal5253. doi: 10.1126/scitranslmed.aal5253. Erratum in: Sci Transl Med. 2017 Jul 26;9(400):.

PMID:
28615361
4.

Androgen receptor in cancer-associated fibroblasts influences stemness in cancer cells.

Liao CP, Chen LY, Luethy A, Kim Y, Kani K, MacLeod AR, Gross ME.

Endocr Relat Cancer. 2017 Apr;24(4):157-170. doi: 10.1530/ERC-16-0138.

5.

Depletion of coagulation factor XII ameliorates brain pathology and cognitive impairment in Alzheimer disease mice.

Chen ZL, Revenko AS, Singh P, MacLeod AR, Norris EH, Strickland S.

Blood. 2017 May 4;129(18):2547-2556. doi: 10.1182/blood-2016-11-753202. Epub 2017 Feb 27.

6.

A Validated Open-Source Multisolver Fourth-Generation Composite Femur Model.

MacLeod AR, Rose H, Gill HS.

J Biomech Eng. 2016 Dec 1;138(12). doi: 10.1115/1.4034653.

PMID:
27618586
7.

Plasmin Prevents Dystrophic Calcification After Muscle Injury.

Mignemi NA, Yuasa M, Baker CE, Moore SN, Ihejirika RC, Oelsner WK, Wallace CS, Yoshii T, Okawa A, Revenko AS, MacLeod AR, Bhattacharjee G, Barnett JV, Schwartz HS, Degen JL, Flick MJ, Cates JM, Schoenecker JG.

J Bone Miner Res. 2017 Feb;32(2):294-308. doi: 10.1002/jbmr.2973. Epub 2016 Dec 5.

8.

Large-diameter total hip arthroplasty modular heads require greater assembly forces for initial stability.

MacLeod AR, Sullivan NP, Whitehouse MR, Gill HS.

Bone Joint Res. 2016 Aug;5(8):338-46. doi: 10.1302/2046-3758.58.BJR-2016-0044.R1.

9.

Image-based detection and targeting of therapy resistance in pancreatic adenocarcinoma.

Fox RG, Lytle NK, Jaquish DV, Park FD, Ito T, Bajaj J, Koechlein CS, Zimdahl B, Yano M, Kopp J, Kritzik M, Sicklick J, Sander M, Grandgenett PM, Hollingsworth MA, Shibata S, Pizzo D, Valasek M, Sasik R, Scadeng M, Okano H, Kim Y, MacLeod AR, Lowy AM, Reya T.

Nature. 2016 Jun 16;534(7607):407-411. doi: 10.1038/nature17988. Epub 2016 Jun 6.

10.

Modulation of tumor eIF4E by antisense inhibition: A phase I/II translational clinical trial of ISIS 183750-an antisense oligonucleotide against eIF4E-in combination with irinotecan in solid tumors and irinotecan-refractory colorectal cancer.

Duffy AG, Makarova-Rusher OV, Ulahannan SV, Rahma OE, Fioravanti S, Walker M, Abdullah S, Raffeld M, Anderson V, Abi-Jaoudeh N, Levy E, Wood BJ, Lee S, Tomita Y, Trepel JB, Steinberg SM, Revenko AS, MacLeod AR, Peer CJ, Figg WD, Greten TF.

Int J Cancer. 2016 Oct 1;139(7):1648-57. doi: 10.1002/ijc.30199. Epub 2016 Jun 27.

11.

Age-related optimization of screw placement for reduced loosening risk in locked plating.

MacLeod AR, Simpson AH, Pankaj P.

J Orthop Res. 2016 Nov;34(11):1856-1864. doi: 10.1002/jor.23193. Epub 2016 Oct 14.

12.

Targeting Long Noncoding RNA with Antisense Oligonucleotide Technology as Cancer Therapeutics.

Zhou T, Kim Y, MacLeod AR.

Methods Mol Biol. 2016;1402:199-213. doi: 10.1007/978-1-4939-3378-5_16.

PMID:
26721493
13.

Differentiation of mammary tumors and reduction in metastasis upon Malat1 lncRNA loss.

Arun G, Diermeier S, Akerman M, Chang KC, Wilkinson JE, Hearn S, Kim Y, MacLeod AR, Krainer AR, Norton L, Brogi E, Egeblad M, Spector DL.

Genes Dev. 2016 Jan 1;30(1):34-51. doi: 10.1101/gad.270959.115. Epub 2015 Dec 23.

14.

AZD9150, a next-generation antisense oligonucleotide inhibitor of STAT3 with early evidence of clinical activity in lymphoma and lung cancer.

Hong D, Kurzrock R, Kim Y, Woessner R, Younes A, Nemunaitis J, Fowler N, Zhou T, Schmidt J, Jo M, Lee SJ, Yamashita M, Hughes SG, Fayad L, Piha-Paul S, Nadella MV, Mohseni M, Lawson D, Reimer C, Blakey DC, Xiao X, Hsu J, Revenko A, Monia BP, MacLeod AR.

Sci Transl Med. 2015 Nov 18;7(314):314ra185. doi: 10.1126/scitranslmed.aac5272.

15.

Reversing Antisense Oligonucleotide Activity with a Sense Oligonucleotide Antidote: Proof of Concept Targeting Prothrombin.

Crosby JR, Zhao C, Zhang H, MacLeod AR, Guo S, Monia BP.

Nucleic Acid Ther. 2015 Dec;25(6):297-305. doi: 10.1089/nat.2015.0560. Epub 2015 Sep 21.

PMID:
26390010
16.

Targeting PYK2 mediates microenvironment-specific cell death in multiple myeloma.

Meads MB, Fang B, Mathews L, Gemmer J, Nong L, Rosado-Lopez I, Nguyen T, Ring JE, Matsui W, MacLeod AR, Pachter JA, Hazlehurst LA, Koomen JM, Shain KH.

Oncogene. 2016 May;35(21):2723-34. doi: 10.1038/onc.2015.334. Epub 2015 Sep 21.

17.

Identification and characterization of modified antisense oligonucleotides targeting DMPK in mice and nonhuman primates for the treatment of myotonic dystrophy type 1.

Pandey SK, Wheeler TM, Justice SL, Kim A, Younis HS, Gattis D, Jauvin D, Puymirat J, Swayze EE, Freier SM, Bennett CF, Thornton CA, MacLeod AR.

J Pharmacol Exp Ther. 2015 Nov;355(2):329-40. doi: 10.1124/jpet.115.226969. Epub 2015 Sep 1.

18.

Generation 2.5 antisense oligonucleotides targeting the androgen receptor and its splice variants suppress enzalutamide-resistant prostate cancer cell growth.

Yamamoto Y, Loriot Y, Beraldi E, Zhang F, Wyatt AW, Al Nakouzi N, Mo F, Zhou T, Kim Y, Monia BP, MacLeod AR, Fazli L, Wang Y, Collins CC, Zoubeidi A, Gleave M.

Clin Cancer Res. 2015 Apr 1;21(7):1675-87. doi: 10.1158/1078-0432.CCR-14-1108. Epub 2015 Jan 29.

19.

Reasons why dynamic compression plates are inferior to locking plates in osteoporotic bone: a finite element explanation.

MacLeod AR, Simpson AH, Pankaj P.

Comput Methods Biomech Biomed Engin. 2015;18(16):1818-25. doi: 10.1080/10255842.2014.974580. Epub 2014 Dec 4.

PMID:
25473732
20.

Preclinical evaluation of the toxicological effects of a novel constrained ethyl modified antisense compound targeting signal transducer and activator of transcription 3 in mice and cynomolgus monkeys.

Burel SA, Han SR, Lee HS, Norris DA, Lee BS, Machemer T, Park SY, Zhou T, He G, Kim Y, MacLeod AR, Monia BP, Lio S, Kim TW, Henry SP.

Nucleic Acid Ther. 2013 Jun;23(3):213-27. doi: 10.1089/nat.2013.0422.

PMID:
23692080
21.

Inhibition of vascular permeability by antisense-mediated inhibition of plasma kallikrein and coagulation factor 12.

Bhattacharjee G, Revenko AS, Crosby JR, May C, Gao D, Zhao C, Monia BP, MacLeod AR.

Nucleic Acid Ther. 2013 Jun;23(3):175-87. doi: 10.1089/nat.2013.0417. Epub 2013 Apr 12.

PMID:
23582057
22.

Antithrombotic effect of antisense factor XI oligonucleotide treatment in primates.

Crosby JR, Marzec U, Revenko AS, Zhao C, Gao D, Matafonov A, Gailani D, MacLeod AR, Tucker EI, Gruber A, Hanson SR, Monia BP.

Arterioscler Thromb Vasc Biol. 2013 Jul;33(7):1670-8. doi: 10.1161/ATVBAHA.113.301282. Epub 2013 Apr 4. Erratum in: Arterioscler Thromb Vasc Biol. 2013 Aug;33(8):e127. Arterioscler Thromb Vasc Biol. 2013 Oct;33(10):e130.

23.

The noncoding RNA MALAT1 is a critical regulator of the metastasis phenotype of lung cancer cells.

Gutschner T, Hämmerle M, Eissmann M, Hsu J, Kim Y, Hung G, Revenko A, Arun G, Stentrup M, Gross M, Zörnig M, MacLeod AR, Spector DL, Diederichs S.

Cancer Res. 2013 Feb 1;73(3):1180-9. doi: 10.1158/0008-5472.CAN-12-2850. Epub 2012 Dec 14.

24.

Targeting nuclear RNA for in vivo correction of myotonic dystrophy.

Wheeler TM, Leger AJ, Pandey SK, MacLeod AR, Nakamori M, Cheng SH, Wentworth BM, Bennett CF, Thornton CA.

Nature. 2012 Aug 2;488(7409):111-5. doi: 10.1038/nature11362.

25.

Does screw-bone interface modelling matter in finite element analyses?

MacLeod AR, Pankaj P, Simpson AH.

J Biomech. 2012 Jun 1;45(9):1712-6. doi: 10.1016/j.jbiomech.2012.04.008. Epub 2012 Apr 25.

PMID:
22537570
26.

Selective depletion of plasma prekallikrein or coagulation factor XII inhibits thrombosis in mice without increased risk of bleeding.

Revenko AS, Gao D, Crosby JR, Bhattacharjee G, Zhao C, May C, Gailani D, Monia BP, MacLeod AR.

Blood. 2011 Nov 10;118(19):5302-11. doi: 10.1182/blood-2011-05-355248. Epub 2011 Aug 5.

27.

Transcription factor Stat5 knockdown enhances androgen receptor degradation and delays castration-resistant prostate cancer progression in vivo.

Thomas C, Zoubeidi A, Kuruma H, Fazli L, Lamoureux F, Beraldi E, Monia BP, MacLeod AR, Thüroff JW, Gleave ME.

Mol Cancer Ther. 2011 Feb;10(2):347-59. doi: 10.1158/1535-7163.MCT-10-0850. Epub 2011 Jan 7.

28.

Inhibition of the intrinsic coagulation pathway factor XI by antisense oligonucleotides: a novel antithrombotic strategy with lowered bleeding risk.

Zhang H, Löwenberg EC, Crosby JR, MacLeod AR, Zhao C, Gao D, Black C, Revenko AS, Meijers JC, Stroes ES, Levi M, Monia BP.

Blood. 2010 Nov 25;116(22):4684-92. doi: 10.1182/blood-2010-04-277798. Epub 2010 Aug 31.

29.

Identification of a novel series of potent RON receptor tyrosine kinase inhibitors.

Raeppel S, Gaudette F, Mannion M, Claridge S, Saavedra O, Isakovic L, Déziel R, Beaulieu N, Beaulieu C, Dupont I, Nguyen H, Wang J, Macleod AR, Maroun C, Besterman JM, Vaisburg A.

Bioorg Med Chem Lett. 2010 May 1;20(9):2745-9. doi: 10.1016/j.bmcl.2010.03.073. Epub 2010 Mar 19.

PMID:
20363625
30.

Identification of potent and selective VEGFR receptor tyrosine kinase inhibitors having new amide isostere headgroups.

Gaudette F, Raeppel S, Nguyen H, Beaulieu N, Beaulieu C, Dupont I, Macleod AR, Besterman JM, Vaisburg A.

Bioorg Med Chem Lett. 2010 Feb 1;20(3):848-52. doi: 10.1016/j.bmcl.2009.12.099. Epub 2010 Jan 4.

PMID:
20071170
31.

N3-arylmalonamides: a new series of thieno[3,2-b]pyridine based inhibitors of c-Met and VEGFR2 tyrosine kinases.

Saavedra O, Claridge S, Zhan L, Raeppel F, Granger MC, Raeppel S, Mannion M, Gaudette F, Zhou N, Isakovic L, Bernstein N, Déziel R, Nguyen H, Beaulieu N, Beaulieu C, Dupont I, Wang J, Macleod AR, Besterman JM, Vaisburg A.

Bioorg Med Chem Lett. 2009 Dec 15;19(24):6836-9. doi: 10.1016/j.bmcl.2009.10.095. Epub 2009 Oct 25.

PMID:
19896842
32.

Constrained (l-)-S-adenosyl-l-homocysteine (SAH) analogues as DNA methyltransferase inhibitors.

Isakovic L, Saavedra OM, Llewellyn DB, Claridge S, Zhan L, Bernstein N, Vaisburg A, Elowe N, Petschner AJ, Rahil J, Beaulieu N, Gauthier F, MacLeod AR, Delorme D, Besterman JM, Wahhab A.

Bioorg Med Chem Lett. 2009 May 15;19(10):2742-6. doi: 10.1016/j.bmcl.2009.03.132. Epub 2009 Mar 28.

PMID:
19364644
33.

SAR around (l)-S-adenosyl-l-homocysteine, an inhibitor of human DNA methyltransferase (DNMT) enzymes.

Saavedra OM, Isakovic L, Llewellyn DB, Zhan L, Bernstein N, Claridge S, Raeppel F, Vaisburg A, Elowe N, Petschner AJ, Rahil J, Beaulieu N, MacLeod AR, Delorme D, Besterman JM, Wahhab A.

Bioorg Med Chem Lett. 2009 May 15;19(10):2747-51. doi: 10.1016/j.bmcl.2009.03.113. Epub 2009 Mar 28.

PMID:
19362833
34.

Discovery of N-(2-aminophenyl)-4-[(4-pyridin-3-ylpyrimidin-2-ylamino)methyl]benzamide (MGCD0103), an orally active histone deacetylase inhibitor.

Zhou N, Moradei O, Raeppel S, Leit S, Frechette S, Gaudette F, Paquin I, Bernstein N, Bouchain G, Vaisburg A, Jin Z, Gillespie J, Wang J, Fournel M, Yan PT, Trachy-Bourget MC, Kalita A, Lu A, Rahil J, MacLeod AR, Li Z, Besterman JM, Delorme D.

J Med Chem. 2008 Jul 24;51(14):4072-5. doi: 10.1021/jm800251w. Epub 2008 Jun 21.

PMID:
18570366
35.

Discovery of a novel and potent series of thieno[3,2-b]pyridine-based inhibitors of c-Met and VEGFR2 tyrosine kinases.

Claridge S, Raeppel F, Granger MC, Bernstein N, Saavedra O, Zhan L, Llewellyn D, Wahhab A, Deziel R, Rahil J, Beaulieu N, Nguyen H, Dupont I, Barsalou A, Beaulieu C, Chute I, Gravel S, Robert MF, Lefebvre S, Dubay M, Pascal R, Gillespie J, Jin Z, Wang J, Besterman JM, MacLeod AR, Vaisburg A.

Bioorg Med Chem Lett. 2008 May 1;18(9):2793-8. doi: 10.1016/j.bmcl.2008.04.009. Epub 2008 Apr 9.

PMID:
18434145
36.

A phase I biological study of MG98, an oligodeoxynucleotide antisense to DNA methyltransferase 1, in patients with high-risk myelodysplasia and acute myeloid leukemia.

Klisovic RB, Stock W, Cataland S, Klisovic MI, Liu S, Blum W, Green M, Odenike O, Godley L, Burgt JV, Van Laar E, Cullen M, Macleod AR, Besterman JM, Reid GK, Byrd JC, Marcucci G.

Clin Cancer Res. 2008 Apr 15;14(8):2444-9. doi: 10.1158/1078-0432.CCR-07-1320.

37.

MGCD0103, a novel isotype-selective histone deacetylase inhibitor, has broad spectrum antitumor activity in vitro and in vivo.

Fournel M, Bonfils C, Hou Y, Yan PT, Trachy-Bourget MC, Kalita A, Liu J, Lu AH, Zhou NZ, Robert MF, Gillespie J, Wang JJ, Ste-Croix H, Rahil J, Lefebvre S, Moradei O, Delorme D, Macleod AR, Besterman JM, Li Z.

Mol Cancer Ther. 2008 Apr;7(4):759-68. doi: 10.1158/1535-7163.MCT-07-2026.

38.

Design and synthesis of 4-[(s-triazin-2-ylamino)methyl]-N-(2-aminophenyl)-benzamides and their analogues as a novel class of histone deacetylase inhibitors.

Paquin I, Raeppel S, Leit S, Gaudette F, Zhou N, Moradei O, Saavedra O, Bernstein N, Raeppel F, Bouchain G, Fréchette S, Woo SH, Vaisburg A, Fournel M, Kalita A, Robert MF, Lu A, Trachy-Bourget MC, Yan PT, Liu J, Rahil J, MacLeod AR, Besterman JM, Li Z, Delorme D.

Bioorg Med Chem Lett. 2008 Feb 1;18(3):1067-71. Epub 2007 Dec 10.

PMID:
18160287
39.

N-(2-Amino-phenyl)-4-(heteroarylmethyl)-benzamides as new histone deacetylase inhibitors.

Vaisburg A, Paquin I, Bernstein N, Frechette S, Gaudette F, Leit S, Moradei O, Raeppel S, Zhou N, Bouchain G, Woo SH, Jin Z, Gillespie J, Wang J, Fournel M, Yan PT, Trachy-Bourget MC, Robert MF, Lu A, Yuk J, Rahil J, Macleod AR, Besterman JM, Li Z, Delorme D.

Bioorg Med Chem Lett. 2007 Dec 15;17(24):6729-33. Epub 2007 Oct 18.

PMID:
17977726
40.

Overcoming resistance to interferon-induced apoptosis of renal carcinoma and melanoma cells by DNA demethylation.

Reu FJ, Bae SI, Cherkassky L, Leaman DW, Lindner D, Beaulieu N, MacLeod AR, Borden EC.

J Clin Oncol. 2006 Aug 10;24(23):3771-9. Epub 2006 Jun 26.

PMID:
16801630
41.

Substituted N-(2-aminophenyl)-benzamides, (E)-N-(2-aminophenyl)-acrylamides and their analogues: novel classes of histone deacetylase inhibitors.

Moradei O, Leit S, Zhou N, Fréchette S, Paquin I, Raeppel S, Gaudette F, Bouchain G, Woo SH, Vaisburg A, Fournel M, Kalita A, Lu A, Trachy-Bourget MC, Yan PT, Liu J, Li Z, Rahil J, MacLeod AR, Besterman JM, Delorme D.

Bioorg Med Chem Lett. 2006 Aug 1;16(15):4048-52. Epub 2006 May 18.

PMID:
16713259
42.

Expression of RASSF1A, an epigenetically silenced tumor suppressor, overcomes resistance to apoptosis induction by interferons.

Reu FJ, Leaman DW, Maitra RR, Bae SI, Cherkassky L, Fox MW, Rempinski DR, Beaulieu N, MacLeod AR, Borden EC.

Cancer Res. 2006 Mar 1;66(5):2785-93.

43.

Release of methyl CpG binding proteins and histone deacetylase 1 from the Estrogen receptor alpha (ER) promoter upon reactivation in ER-negative human breast cancer cells.

Sharma D, Blum J, Yang X, Beaulieu N, Macleod AR, Davidson NE.

Mol Endocrinol. 2005 Jul;19(7):1740-51. Epub 2005 Mar 3.

PMID:
15746193
44.

(2-amino-phenyl)-amides of omega-substituted alkanoic acids as new histone deacetylase inhibitors.

Vaisburg A, Bernstein N, Frechette S, Allan M, Abou-Khalil E, Leit S, Moradei O, Bouchain G, Wang J, Woo SH, Fournel M, Yan PT, Trachy-Bourget MC, Kalita A, Beaulieu C, Li Z, MacLeod AR, Besterman JM, Delorme D.

Bioorg Med Chem Lett. 2004 Jan 5;14(1):283-7.

PMID:
14684344
45.

A phase I pharmacokinetic and pharmacodynamic study of the DNA methyltransferase 1 inhibitor MG98 administered twice weekly.

Stewart DJ, Donehower RC, Eisenhauer EA, Wainman N, Shah AK, Bonfils C, MacLeod AR, Besterman JM, Reid GK.

Ann Oncol. 2003 May;14(5):766-74.

PMID:
12702532
46.

Development of potential antitumor agents. Synthesis and biological evaluation of a new set of sulfonamide derivatives as histone deacetylase inhibitors.

Bouchain G, Leit S, Frechette S, Khalil EA, Lavoie R, Moradei O, Woo SH, Fournel M, Yan PT, Kalita A, Trachy-Bourget MC, Beaulieu C, Li Z, Robert MF, MacLeod AR, Besterman JM, Delorme D.

J Med Chem. 2003 Feb 27;46(5):820-30.

PMID:
12593661
47.

DNMT1 is required to maintain CpG methylation and aberrant gene silencing in human cancer cells.

Robert MF, Morin S, Beaulieu N, Gauthier F, Chute IC, Barsalou A, MacLeod AR.

Nat Genet. 2003 Jan;33(1):61-5. Epub 2002 Dec 23.

PMID:
12496760
48.

Sulfonamide anilides, a novel class of histone deacetylase inhibitors, are antiproliferative against human tumors.

Fournel M, Trachy-Bourget MC, Yan PT, Kalita A, Bonfils C, Beaulieu C, Frechette S, Leit S, Abou-Khalil E, Woo SH, Delorme D, MacLeod AR, Besterman JM, Li Z.

Cancer Res. 2002 Aug 1;62(15):4325-30.

49.

Selective inhibition of DNA methyltransferase enzymes as a novel strategy for cancer treatment.

Reid GK, Besterman JM, MacLeod AR.

Curr Opin Mol Ther. 2002 Apr;4(2):130-7. Review.

PMID:
12044034
50.

An essential role for DNA methyltransferase DNMT3B in cancer cell survival.

Beaulieu N, Morin S, Chute IC, Robert MF, Nguyen H, MacLeod AR.

J Biol Chem. 2002 Aug 2;277(31):28176-81. Epub 2002 May 15.

Supplemental Content

Loading ...
Support Center